scpharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (iv) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.
Company profile
Ticker
SCPH
Exchange
Website
CEO
John Tucker
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
scPharmaceuticals Securities Corporation ...
SCPH stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
25 Mar 24
424B5
Prospectus supplement for primary offering
22 Mar 24
S-8
Registration of securities for employees
13 Mar 24
S-3
Shelf registration
13 Mar 24
10-K
2023 FY
Annual report
13 Mar 24
8-K
Generated full-year net FUROSCIX® revenue of $13.6 million, at the upper end of the range provided in January
13 Mar 24
8-K
Gross-to-net (GTN) discount of approximately 18% from launch through the end of Q4
4 Jan 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Results of Operations and Financial Condition
8 Nov 23
8-K
Entry into a Material Definitive Agreement
20 Sep 23
Latest ownership filings
SC 13G/A
5AM Ventures IV, L.P.
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G
Rubric Capital Management LP
12 Feb 24
SC 13G/A
HIRSCHMAN ORIN
7 Feb 24
SC 13G
BlackRock Inc.
2 Feb 24
SC 13G/A
Cowen Financial Products LLC
2 Feb 24
4
Rachael Nokes
22 Jan 24
4
John H Tucker
22 Jan 24
SC 13G/A
MILLENNIUM MANAGEMENT LLC
12 Jan 24
4
Rachael Nokes
3 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 35.04 mm | 35.04 mm | 35.04 mm | 35.04 mm | 35.04 mm | 35.04 mm |
Cash burn (monthly) | 12.10 mm | 535.75 k | 4.95 mm | 4.14 mm | 4.48 mm | 4.66 mm |
Cash used (since last report) | 72.22 mm | 3.20 mm | 29.52 mm | 24.69 mm | 26.76 mm | 27.81 mm |
Cash remaining | -37.18 mm | 31.84 mm | 5.53 mm | 10.36 mm | 8.29 mm | 7.23 mm |
Runway (months of cash) | -3.1 | 59.4 | 1.1 | 2.5 | 1.8 | 1.6 |
Institutional ownership, Q2 2023
99.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 85 |
Opened positions | 34 |
Closed positions | 14 |
Increased positions | 21 |
Reduced positions | 17 |
13F shares | Current |
---|---|
Total value | 289.50 bn |
Total shares | 35.82 mm |
Total puts | 54.40 k |
Total calls | 90.80 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Orbimed Advisors | 5.56 mm | $56.65 bn |
RTW Investments | 3.30 mm | $33.61 bn |
Hirschman Orin | 2.55 mm | $17.78 mm |
Cowen Financial Products | 2.41 mm | $22.63 mm |
5AM Ventures IV | 2.32 mm | $0.00 |
AIGH Capital Management | 2.05 mm | $20.91 bn |
Cowen And | 1.84 mm | $18.73 bn |
BLK Blackrock | 1.73 mm | $17.62 bn |
Millennium Management | 1.22 mm | $12.39 bn |
5AM Venture Management | 1.20 mm | $12.23 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Jan 24 | Tucker John H | Common Stock | Grant | Acquire A | No | No | 0 | 113,560 | 0.00 | 254,207 |
18 Jan 24 | Tucker John H | Stock Option Common Stock | Grant | Acquire A | No | No | 5.76 | 170,340 | 981.16 k | 170,340 |
18 Jan 24 | Rachael Nokes | Common Stock | Grant | Acquire A | No | No | 0 | 41,840 | 0.00 | 62,406 |
18 Jan 24 | Rachael Nokes | Stock Option Common Stock | Grant | Acquire A | No | No | 5.76 | 62,755 | 361.47 k | 62,755 |
2 Jan 24 | Tucker John H | Common Stock | Payment of exercise | Dispose F | No | No | 6.39 | 4,942 | 31.58 k | 140,647 |
2 Jan 24 | Rachael Nokes | Common Stock | Payment of exercise | Dispose F | No | No | 6.39 | 1,027 | 6.56 k | 20,566 |
6 Jun 23 | Mette Kirstine Agger | Stock Option Common Stock | Grant | Acquire A | No | No | 11.71 | 17,300 | 202.58 k | 17,300 |
News
HC Wainwright & Co. Reiterates Buy on scPharmaceuticals, Maintains $18 Price Target
14 Mar 24
Recap: scPharmaceuticals Q4 Earnings
13 Mar 24
scPharmaceuticals Q4 2023 GAAP EPS $(0.35) Beats $(0.42) Estimate, Sales $6.096M Beat $5.525M Estimate
13 Mar 24
Earnings Scheduled For March 13, 2024
13 Mar 24
A Preview Of scPharmaceuticals's Earnings
12 Mar 24
Press releases
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
13 Mar 24
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024
6 Mar 24
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
28 Feb 24
scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue
4 Jan 24